Extended Anticoagulation with Reduced-Dose Non-inferior to Full-Dose Apixaban for the Prevention of Recurrent VTE in Patients with Active Cancer By Ogkologos - April 29, 2025 593 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the API-CAT study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Pembrolizumab with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma MOST POPULAR Being Diagnosed With a Childhood Cancer As an Adult Led Me... May 18, 2023 Does Too Much Fructose Help Colorectal Cancers Grow? October 29, 2021 FDA Approves Companion Diagnostic to Identify NTRK Fusions in Solid Tumours... October 29, 2020 Can cancer cells communicate? February 28, 2023 Load more HOT NEWS Metastatic Breast Cancer: New ESMO Guideline With Evidence-Based Recommendations [ESMO Press... Study Links Non-Diet Soda Consumption with a Higher Risk of Death... Axicabtagene Ciloleucel Results in High Response Rates and Durable Remissions as... Scientists Link a Single Type of Bacteria to Colorectal Cancer
